(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -12.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 28.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.17%.
Sarepta Therapeutics's revenue in 2026 is $1,956,339,000.On average, 26 Wall Street analysts forecast SRPT's revenue for 2026 to be $203,533,639,504, with the lowest SRPT revenue forecast at $189,164,035,872, and the highest SRPT revenue forecast at $214,257,224,304. On average, 26 Wall Street analysts forecast SRPT's revenue for 2027 to be $153,883,441,880, with the lowest SRPT revenue forecast at $129,969,847,776, and the highest SRPT revenue forecast at $187,233,790,608.
In 2028, SRPT is forecast to generate $148,628,885,328 in revenue, with the lowest revenue forecast at $111,310,810,224 and the highest revenue forecast at $183,802,243,472.